Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats

Digestive Diseases and Sciences

Volumn 54, Issue 4, 2009, Pages 758-766

  Ancha, Hanumantha R ^a   Kurella, Ravi R ^a   McKimmey, Christine C ^a   Lightfoot, Stanley ^a   Harty, Richard F ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

INOS in colitis; N acetylcysteine plus mesalamine; PGE2

Indexed keywords

ACETYLCYSTEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MESALAZINE; MYELOPEROXIDASE; PROSTAGLANDIN E2; TRINITROBENZENESULFONIC ACID; MEMBRANE PROTEIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NOS2 PROTEIN, RAT; PTGS1 PROTEIN, RAT; PTGS2 PROTEIN, RAT; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REPRESSION; ENZYME SYNTHESIS; GENE EXPRESSION; HISTOLOGY; INFLAMMATION; INTESTINE MUCOSA; MALE; MONOTHERAPY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT; WOUND HEALING; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COLON; COMPARATIVE STUDY; DRUG COMBINATION; ENZYMOLOGY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACETYLCYSTEINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLON; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DRUG THERAPY, COMBINATION; FREE RADICAL SCAVENGERS; INTESTINAL MUCOSA; MALE; MEMBRANE PROTEINS; MESALAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TRINITROBENZENESULFONIC ACID;

EID: 63249104523     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0438-0     Document Type: Article

References (36)

1. C Fiocchi 2005 The multiple components of inflammatory bowel disease pathogenesis: should we invest in all of them or should we pick and choose? Curr Opin Gastroenterol 21 399 400
2. C Fiocchi 2006 Non-stop progress in inflammatory bowel disease: new players, new understanding, new therapies Curr Opin Gastroenterol 22 347 348 10.1097/01.mog.0000231805.65030.36
3. J Puleston M Cooper S Murch 2005 A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease Aliment Pharmacol Ther 21 109 120 10.1111/j.1365-2036.2004.02262.x
4. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission of Crohns disease. Cochrane Database Syst Rev. 2004;CD003574.
5. HO Collier AA Francis WJ [tmp] McDonald-Gibson SA Saeed 1976 Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites Prostaglandins 11 219 225 10.1016/0090-6980(76)90145-3
6. P Sharon M Ligumsky D Rachmilewitz U Zor 1978 Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine Gastroenterology 75 638 640
7. I Ahnfelt-Ronne OH Nielsen A Christensen E Langholz V Binder P Riis 1990 Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid Gastroenterology 98 1162 1169
8. H Bantel C Berg M Vieth M Stolte K Schulze-Osthoff 2000 Mesalamine inhibits activation of transcription factor NF-kB in inflamed mucosa of patients with ulcerative colitis Am J Gastroenterol 95 3452 3457
9. MB Grisham 1994 Oxidants and free radicals in inflammatory bowel disease Lancet B44 859 861 10.1016/S0140-6736(94)92831-2
10. D Rachmilewitz F Karmeli M Bursztyn 1995 Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity Gut 37 247 255 10.1136/gut.37.2.247
11. A Keshavarzian G Morgan S Sedghi JH Gordon M Doria 1990 Role of reactive oxygen metabolites in experimental colitis Gut 31 786 790 10.1136/gut.31.7.786
12. A Siddiqui HR Ancha D Tedesco S Lightfoot C Stewart RF Harty 2006 Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosa healing in a rodent model of colitis Dig Dis Sci 51 698 705 10.1007/s10620-006- 3194-z
13. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 417 429 10.1056/NEJMra020831
14. RP [tmp] MacDermott 2000 Progress in understanding the mechanisms of action of 5-aminosalicylic acid Am J Gastroenterol 95 3343 3345 10.1111/j.1572-0241.2000.03342.x
15. E Ardite M Sans J Panés FJ Romero JM Pique JC Fernadez-Checa 2000 Replenishment of glutathione levels improves mucosal function in experimental acute colitis Lab Invest 80 735 744
16. Y Naito T Takagi T Ashikawa 2002 α Phenyl-N-tert-butylnitrone provides protection from dextran sulfate sodium-induced colitis in mice Antioxid Redox Signal 4 195 206 10.1089/152308602753625951
17. DM [tmp] McCafferty E Shiota 1999 Role of inducible nitric oxide synthase in trinitrobenzene sulfonic acid induced colitis in mice Gut 45 199 209
18. P Sharon WF Stenson 1984 Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease Gastroenterology 86 453 460
19. II Singer DW Kawka S Schloemann T Tessner T Riehl WF Stenson 1998 Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease Gastroenterology 115 297 306 10.1016/S0016-5085(98)70196-9
20. BK Reuter S Asfaha A Buret KA Sharkey JL Wallace 1996 Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2 J Clin Invest 98 2076 2085 10.1172/JCI119013
21. CF Krieglstein WH Cerwinka JW Salter 2001 Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide J Exp Med 194 1207 1218 10.1084/jem.194.9.1207
22. L Kruidenier I Kuiper CBHW Lamers HW Verspaget 2003 Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants J Pathol 201 28 36 10.1002/path.1409
23. WF Stenson 2007 Prostaglandins and epithelial response to injury Curr Opin Gastroenterol 23 107 110 10.1097/MOG.0b013e3280143cb6
24. M Fukata A Chen A Klepper 2006 COX-2 is regulated by toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine Gastroenterology 131 862 877 10.1053/j.gastro.2006.06.017
25. GF Bonner 2002 Using COX-2 inhibitors in IBD: anti-inflammatories infame a controversy Am J Gastroenterol 97 783 785 10.1111/j.1572-0241.2002.05592.x
26. R Tsubouchi S Hayashi Y Aoi 2006 Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats Digestion 74 91 100 10.1159/000097657
27. 2 in the acute, chronic and recovery phase of murine experimental colitis Cytokine 35 275 283 10.1016/j.cyto.2006.09.007
28. 2 in experimental inflammatory bowel disease is mediated through the IL-23-IL-17 axis J Immunol 178 8138 8147
29. L Zhang YM Lu XY Dong 2004 Effects and mechanisms of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid Chin J Dig Dis 5 110 114 10.1111/j.1443-9573.2004.00164.x
30. Z Zhang A Andoh O Inatomi N Shimizu Y Fujiyama 2005 Interleukin-17 and lipopolysaccharides synergistically induce cyclooxygenase-2 expression in human intestinal myofibroblasts J Gastro Hepatol 20 619 627 10.1111/j.1440-1746.2004. 03748.x
31. S Yedgar M Krimsky Y Cohen RJ Flower 2007 Treatment of inflammatory diseases by selective eicosanoid inhibition: a double edged sword? Trends Pharmacol Sci 28 459 464 10.1016/j.tips.2007.07.005
32. F Celotti S Laufer 2001 Anti-inflammatory drugs: new multi target compounds to face an old problem. The dual inhibition concept Pharmacol Res 43 429 436 10.1006/phrs.2000.0784
33. F Celotti T Durand 2003 The metabolic effects of inhibition of 5-lipoxygenase and cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy Prostaglandins Other Lipid Mediat 71 147 162
34. GW Dryden Jr I Deaciuc G Arteel CJ [tmp] McClain 2007 Clinical implications of oxidative stress and antioxidant therapy Curr Gastroenterol Rep 7 306 316
35. CF Kreiglstein C Anthoni WH Cerwinka KY Stokes J Russell MB Grisham DN Granger 2007 Role of blood-and tissue-associated inducible nitric-oxide synthase in colonic inflammation Am J Pathol 170 490 496
36. 2 through enhancement of NF-kB activity in lipopolysaccharide-activated human primary monocytes J Immunol 175 5423 5429